Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2012
Reporting Period: Event date January 27, 2012; Signed February 1, 2012.
The Company entered into a Material Definitive Agreement with Regenerative Sciences, LLC ("RS") to acquire exclusive licenses for medical device technology and cell culturing methods related to disc and spine repair.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. No revenue, profit, cash flow, or margin data is provided in this document.
- License Fee Obligation: $990,000 (net) payable to RS at closing.
- Equity Issuance: Warrant issued to RS for the purchase of 50,000,000 shares of common stock.
- Debt and Liquidity: The filing text does not provide a clear value for current debt or liquidity positions. However, the closing of the agreement is contingent upon the Company securing financing to pay the initial license fee.
Material Changes
The primary material change is the execution of the License Agreement with Regenerative Sciences, LLC. Key terms include:
- Worldwide Exclusive License: Rights to utilize or sublicense a medical device for cell administration to the disc/spine.
- Regional Exclusive License: Rights to utilize or sublicense a cell culturing method (excluding Asia and Argentina).
- Conditions: Maintenance of exclusivity requires achieving certain milestones or paying minimum royalty amounts.
- Support: RS will provide training, assistance, and consultation services.
Guidance, Outlook, and Risks
Outlook and Closing Conditions: The agreement contemplates a closing in March 2012. This closing is subject to the satisfaction of conditions, specifically the receipt of financing by the Company to fund the $990,000 license fee.
Risks and Contingencies:
- Financing Risk: The transaction is contingent on the Company's ability to raise capital.
- Dilution Risk: The issuance of a warrant for 50,000,000 shares represents a significant potential dilution to existing shareholders.
- Performance Risk: The Company must meet specific milestones or royalty payments to maintain the exclusive nature of the licenses.
Management Commentary: The Company issued a press release on January 31, 2012, announcing the agreement. The filing explicitly states that the information is furnished, not filed, and does not constitute an admission of materiality for investment decisions.
Investor Verification Checklist
- Verify the Company's current cash position and ability to secure the financing required to close the $990,000 license fee by March 2012.
- Review the specific terms of the warrant issued for 50,000,000 shares (exercise price, expiration, and dilution impact).
- Assess the feasibility of the milestones required to maintain the exclusive licenses.
- Confirm the status of the press release dated January 31, 2012, for additional details not included in the 8-K text.